After a research note raised potential safety concerns with Amgen's lead obesity candidate, the company defended its drug and ...

(Reuters) -Merck has signed a licensing agreement worth up to $3.3 billion with Shanghai-based LaNova Medicines to develop, make and sell an experimental cancer drug, the two companies said on ...

Tempus AI's growth and partnerships make it an attractive investment. See why TEM stock is a solid Buy due to its ...

In the judge's view, the changes to the 'tick' device and the font, strapline and colours in the logo variants did not alter ...

InProcess-LSP are a young organization, founded in 2014, they have since emerged as providers of groundbreaking process analytical technology for nanoparticle characterization. This article provides a ...

Naturally, it's early days for Summit and ivonescimab, but it is probably no coincidence that Merck stock has slipped from nearly $120 per share, to $105 since Akeso's data was released.

many of them called for Nike to design custom kits for the World No. 1. Now, in her Instagram stories, Aryna Sabalenka seemingly teased a new custom logo. She posted a photo of her Nike shoes ...

Despite Merck & Co. homing in on approval for its infant ... “what’s very nice about these data is that there is no waning efficacy,” Triomphe pointed out. “After six months, we still ...

Merck's recently approved vaccine, however, gives Pfizer some major competition. The shot, called Capvaxive, protects against bacterial strains that cause about 84% of cases of adult pneumoccocal ...

Merck’s acquisition of Modifi Biosciences will give it access to preclinical cancer drug candidates that target DNA repair processes. Modifi Biosciences, a spin out of Yale University founded in 2021, ...

Oct. 23, 2024 (GLOBE NEWSWIRE) -- Modifi Biosciences, Inc. (“Modifi Biosciences”), a leader in the development of direct DNA modification enabled cancer therapeutics, today announced that the company ...